Gilead Sciences to Acquire Arcellx to Maximize Long Term Potential of Anito cel

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied e... [13799 chars]